biostudies-literatureUnknown6(23)Khanna AResidual androgen receptor (AR)-signaling and presence of cancer stem-like cells (SCs) are the two emerging paradigms for clinically challenging castration-resistant prostate cancer (CRPC). Therefore, identification of AR-target proteins that are also overexpressed in the cancer SC population would be an attractive therapeutic approach.Our analysis of over three hundred clinical samples and patient-derived prostate epithelial cultures (PPECs), revealed Cancerous inhibitor of protein phosphatase 2A (CIP2A) as one such target. CIP2A is significantly overexpressed in both hormone-naïve prostate cancer (HN-PC) and CRPC patients . CIP2A is also overexpressed, by 3- and 30-fold, in HN-PC and CRPC SCs respectively. In vivo binding of the AR to the intronic region of CIP2A and its functionality inOncotarget19661-70https://www.ebi.ac.uk/biostudies/studies/S-EPMC4637312biostudies-literatureCIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.PMC4637312Kivinummi KKHelenius MAMaitland NJTolonen TTManni VLatonen LSaramaki ORVisakorpi TKhanna AUrbanucci APimanda JERane JKWestermarck JfalseCIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.Residual androgen receptor (AR)-signaling and presence of cancer stem-like cells (SCs) are the two emerging paradigms for clinically challenging castration-resistant prostate cancer (CRPC). Therefore, identification of AR-target proteins that are also overexpressed in the cancer SC population would be an attractive therapeutic approach.Our analysis of over three hundred clinical samples and patient-derived prostate epithelial cultures (PPECs), revealed Cancerous inhibitor of protein phosphatase 2A (CIP2A) as one such target. CIP2A is significantly overexpressed in both hormone-naïve prostate cancer (HN-PC) and CRPC patients . CIP2A is also overexpressed, by 3- and 30-fold, in HN-PC and CRPC SCs respectively. In vivo binding of the AR to the intronic region of CIP2A and its functionality in2015-01-01T00:00:00Z2015 Aug2026-05-09T15:49:56.041Z2019-03-27T02:01:33ZS-EPMC46373122596583410.18632/oncotarget.3875